This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Some patients with aortic stenosis may require multiple valve interventions in their lifetime, and choosing transcatheter aortic valve replacement (TAVR) as the initial intervention may be appealing to many. If their transcatheter heartvalve degenerates later in life, most will hope to undergo redo-TAVR.
IntroductionSince TAVR was approved for lower-risk aortic stenosis (AS) patients, managing post-implantation conduction disturbances has become crucial, especially with self-expanding heartvalves (SEV).
Small aortic annulus poses a major challenge in aortic valve replacement due to the increased risk of prosthesispatient mismatch (PPM) and increased surgical risk. In recent years, transcatheter aortic valve replacement (TAVR) has emerged as a popular alternative to the traditional surgical aortic valve replacement.
What are the rates of a permanent pacemaker (PPM) implantation, the predictors of needing a PPM, and long-term clinical outcomes of the third-generation balloon-expandable SAPIEN 3 (S3) transcatheter heartvalve (THV)?
The fifth-generation SAPIEN 3 Ultra Resilia valve (S3UR) transcatheter heartvalve (THV), used in TAVR procedures, is associated with lower mean gradients and lower rates of paravalvular leak (PVL) when compared to outcomes from the SAPIEN 3 (S3) and SAPIEN 3 Ultra (S3U) valves, according to a study presented at CRT 2024 and simultaneously published (..)
milla1cf Tue, 03/12/2024 - 16:48 March 12, 2024 — Medtronic plc , a global leader in healthcare technology, today announced two late-breaking data presentations on four-year outcomes from the Evolut Low Risk Trial. The findings showed a strong economic benefit of Evolut TAVR for low-risk patients from a U.S.
BACKGROUND:Transcatheter heartvalve (THV) underexpansion after transcatheter aortic valve replacement may be associated with worse outcomes. Circulation: Cardiovascular Interventions, Ahead of Print.
Transcatheter aortic valve replacement (TAVR) is increasingly being performed in younger and lower surgical risk patients. Reintervention for failed transcatheter heartvalves will likely increase in the future as younger patients are expected to outlive the initial bioprosthesis.
The SMART trial is the first randomized head-to-head comparison of the two most widely used TAVR devices—the supra-annular self-expanding Evolut PRO/PRO+/FX and the balloon-expandable SAPIEN 3/3 Ultra. percentage points—in one-year bioprosthetic valve dysfunction favoring the Evolut platform. of those receiving the SAPIEN valve.
We believe the tools, resources, and information shared at the meeting will provide the healthcare community with greater expertise to improve patient outcomes and also connect with their interventional cardiology colleagues,” said SCAI President George D. About 276,000 patients have undergone a TAVR procedure in the United States.
In light of the growing number of patients undergoing transcatheter aortic valve replacement (TAVR), there is an increasing demand for data regarding the management of failed TAVR procedures, including the possibility of a repeat TAVR intervention. vs. 3.5%, p=0.80) between the redo-TAVR and native-TAVR populations.
Adult Cardiac Surgery Database Lead Author Title Publication Date Jacob Raphael Red Blood Cell Transfusion and Pulmonary Complications: The Society of Thoracic Surgeons Adult Cardiac Surgery Database Analysis The Annals of Thoracic Surgery January 2024 Joseph Sabik Multi-Arterial versus Single-Arterial Coronary Surgery: Ten Year Follow-up of One Million (..)
Program Designations Access and Publications (A&P) 1 Participant User File (PUF) 2 Task Force on Funded Research (TFR) 3 Special Projects 4 Adult Cardiac Surgery Database Lead Author Title Publication Date William Keeling 2 National Trends in Emergency Coronary Artery Bypass Grafting European Journal of Cardiothoracic Surgery October 2023 Jake (..)
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
73 
Let's personalize your content